ClinicalTrials.gg
CompletedNCT06115902Updated Jul 8, 2026

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

A Phase 1 interventional study of TQB2102 for injection in Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Completed at 20 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited — 11 open to participants now, 16 under way, 8 of them phase 3. Breast Neoplasms · Sino Biopharmaceutical Limited.

Enrollment
14th of 28
153 · median 138
Started
2023
with 4 others
Phase 1
8 of 28
3 open now
Registered
13th of 28
by date

Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 14th largest by enrollment, is one of 5 that started in 2023, is one of 8 in phase 1, and was the 13th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 1/Phase 2 study to evaluate the effectiveness, safety, pharmacokinetics (PK) and anti-drug antibody (ADA) of TQB2102 for injection in subjects with HER2-expressing relapsed/metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participate in this study and sign ;
  • Between the ages of 18-75 years (subject to the date of signing the informed consent); (ECOG) score 0-1; estimated survival time ≥3 months;
  • Breast cancer patients diagnosed with expression by pathological examination, with evidence of local focal recurrence or distant , are not suitable for surgery or radiotherapy for cure;
  • Disease progression or intolerance during or after the most recent treatment period must be present before participating in clinical trials;
  • At least one (based on 1.1);
  • The main organs function are normally;
  • Female participants of childbearing age should agree to use during the study period and for 6 months after the end of the study; Have a negative serum pregnancy test within 7 days prior to study enrollment and must be a non-lactating subject; Male participants should agree that contraception must be used during the study period and for 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Concomitant disease and medical history:

    1. Has diagnosed and/or treated additional within 3 years prior to first administration of study drug;
    2. Adverse effects due to any prior treatment have not been restored according to CommonTerminology Criteria for Adverse Events () 5.0 ≤ level 1 (Excluding hair loss);
    3. Major surgical treatment, incision , or significant traumatic injury received within 28 days prior to study treatment;
    4. Long-term unhealed wounds or fractures;
    5. Patients who have a prior history of interstitial lung disease/pneumonia requiring intervention, or who are present with interstitial lung disease/pneumonia, or who are suspected of having interstitial lung disease/pneumonia on screening imaging and cannot be ruled out;
    6. Arterial/venous thrombosis events, such as cerebrovascular accident, deep vein thrombosis, and pulmonary embolism, occurred within 6 months before the first medication;
    7. Patients who have a history of psychotropic substance abuse and are unable to abstain or have mental disorders;
    8. Patients with any severe and/or uncontrolled disease;
  • Tumor related symptoms and treatment:

    1. Patients who have been treated with other antitumor drug, such as chemotherapy, radical radiotherapy, or immunotherapy, within 4 weeks prior to the first dose, or who are still within 5 half-lives of the drug;
    2. Received Chinese patent drugs with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 week before the study treatment;
    3. Patients whose imaging shows that the tumor has invaded important blood vessels or who are determined by the investigators to be highly likely to invade important blood vessels during follow-up studies and cause fatal major bleeding;
    4. Uncontrolled pleural effusion, ascites, and moderate or higher pericardial effusion requiring repeated drainage;
    5. Known presence of cancerous meningitis or clinically active central nervous system ; Patients who have been stable for at least 4 weeks after treatment and have been off corticosteroids for at least 2 weeks are excluded;
    6. Patients with severe bone injury due to tumor bone metastasis;
  • Study treatment related: people who are known to be allergic to the study drug or its , or to humanized monoclonal antibody products;
  • Patients who participated in and used other anti-tumor clinical trials within 4 weeks before the first medication;
  • In the judgment of the investigator, there is a situation that seriously endangers the safety of the subjects or affects the completion of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    TQB2102 for injection

    Dose: 6.0 mg/kg or 7.5 mg/kg of TQB2102 for injection. Administration: Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle.

    Drug: TQB2102 for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR defined as percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: Baseline up to 10 months.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS defined as the time from the first injection until the first documented progressive disease (PD) or death from any cause, whichever happens first.

    Time frame: Baseline up to 14 months.

  2. Duration of Remission (DOR)

    DOR defined as the time when the participants first achieved complete or partial remission to disease progression.

    Time frame: Baseline up to 14 months.

  3. Disease Control Rate (DCR)

    Percentage of participants achieving complete response (CR), partial response (PR) and stable disease (SD).

    Time frame: Baseline up to 10 months.

  4. Clinical Benefit Rate (CBR)

    Percentage of participants achieving complete response (CR), partial response (PR) and stable disease (SD) for ≥ 24 weeks.

    Time frame: Baseline up to 14 months.

  5. Overall Survival (OS)

    OS defined as the time from the first injection to death from any cause.

    Time frame: Baseline up to 20 months.

  6. Incidence of adverse event (AE)

    The occurrence of all adverse medical events after the first injection.

    Time frame: From the date of signing the informed consent to 28 days after the last dosing or a new anti-tumor treatment, whichever comes first.

  7. Severity of adverse event (AE)

    The severity of all adverse medical events after the first injection.

    Time frame: From the date of signing the informed consent to 28 days after the last dosing or a new anti-tumor treatment, whichever comes first.

  8. Concentration of TQB2102

    Serum concentration of TQB2102

    Time frame: 0 to 1 hour before infusion and 0.5 to 2 hours after infusion on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Cycle 7 Day 1. Each cycle is 21 days.

  9. Concentration of total antibody

    Total antibody concentration in serum

    Time frame: 0 to 1 hour before infusion and 0.5 to 2 hours after infusion on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Cycle 7 Day 1. Each cycle is 21 days.

  10. Small molecule toxin

    Small molecule toxin in plasma

    Time frame: 0 to 1 hour before infusion and 0.5 to 2 hours after infusion on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1 and Cycle 7 Day 1. Each cycle is 21 days.

  11. Anti-drug antibody (ADA)

    Incidence of anti-drug antibody (ADA)

    Time frame: Before infusion on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 7 Day 1, Cycle 12 Day 1, 30 days after the end of the last infusion. Each cycle is 21 days.

07

Study locations

20 sites
  • Anhui Pronvincial Cancer Hospital
    Hefei, Anhui 230000, China
  • Lu'an People's Hospital
    Lu'an, Anhui 237008, China
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing Municipality 100021, China
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Jiangmen Central Hospital
    Jiangmen, Guangdong 529000, China
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi 530021, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
  • Ganzhou People's Hospital
    Ganzhou, Jiangxi 341000, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110000, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Cancer Hospital Affiliated to Shandong First Medical University
    Jinan, Shandong 250117, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276034, China
  • The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
    Xi'an, Shannxi 710089, China
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 030000, China
  • Suining Central Hospital
    Suining, Sichuan 629000, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300202, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Feb 2025, 14 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 14 months is below that.

Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Nov 3, 2023
StartActual
Nov 17, 2023
Primary completionActual
Feb 1, 2025
CompletionActual
Feb 1, 2025
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06115902
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Nov 17, 2023
Primary completion
Feb 1, 2025
Completion
Feb 1, 2025
Last update
Jul 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102

Start the discussion